Glaukos Stock Forecast, Price & News

Glaukos (NYSE:GKOS) Frequently Asked Questions

Is Glaukos a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View analyst ratings for Glaukos or view top-rated stocks.

How has Glaukos' stock been impacted by COVID-19 (Coronavirus)?

Glaukos' stock was trading at $38.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GKOS stock has increased by 33.0% and is now trading at $51.38.
View which stocks have been most impacted by COVID-19.

When is Glaukos' next earnings date?

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Glaukos.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) issued its earnings results on Thursday, November, 4th. The medical instruments supplier reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.37. The medical instruments supplier had revenue of $74.71 million for the quarter, compared to analyst estimates of $72.73 million. Glaukos had a negative trailing twelve-month return on equity of 4.12% and a negative net margin of 13.05%. The business's revenue for the quarter was up 15.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.09) EPS.
View Glaukos' earnings history.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos issued an update on its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $285 million-$290 million, compared to the consensus revenue estimate of $287.86 million.

What price target have analysts set for GKOS?

9 Wall Street analysts have issued 1-year price targets for Glaukos' shares. Their forecasts range from $34.00 to $105.00. On average, they anticipate Glaukos' share price to reach $59.00 in the next year. This suggests a possible upside of 14.8% from the stock's current price.
View analysts' price targets for Glaukos or view top-rated stocks among Wall Street analysts.

Who are Glaukos' key executives?

Glaukos' management team includes the following people:

• Thomas William Burns, President, Chief Executive Officer & Director
• Chris M. Calcaterra, Chief Operating Officer
• Joseph E. Gilliam, CFO, CAO & Senior VP-Corporate Development (LinkedIn Profile)
• L. Jay Katz, Chief Medical Officer
• Tomas Navratil, Senior Vice President-Research & Development

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among Glaukos' employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Glaukos' key competitors?

Some companies that are related to Glaukos include Penumbra (PEN), Tandem Diabetes Care (TNDM), NovoCure (NVCR), Globus Medical (GMED), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ShockWave Medical (SWAV), ICU Medical (ICUI), iRhythm Technologies (IRTC), Inari Medical (NARI), Merit Medical Systems (MMSI), Nevro (NVRO), NuVasive (NUVA), AtriCure (ATRC) and Haemonetics (HAE).
View all of GKOS's competitors.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a variety of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (1.18%), Taylor Frigon Capital Management LLC (0.23%), Exchange Traded Concepts LLC (0.18%), State of Alaska Department of Revenue (0.07%), Louisiana State Employees Retirement System (0.05%) and Baillie Gifford & Co. (0.02%). Company insiders that own Glaukos stock include Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos.

Which institutional investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Cutler Group LP, and State of Alaska Department of Revenue.
View insider buying and selling activity for Glaukos or view top insider-selling stocks.

Which institutional investors are buying Glaukos stock?

GKOS stock was purchased by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Riverbridge Partners LLC, Louisiana State Employees Retirement System, and Taylor Frigon Capital Management LLC.
View insider buying and selling activity for Glaukos or or view top insider-buying stocks.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $51.38.

How much money does Glaukos make?

Glaukos has a market capitalization of $2.41 billion and generates $224.96 million in revenue each year. The medical instruments supplier earns $-120.35 million in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Glaukos have?

Glaukos employs 653 workers across the globe.

What is Glaukos' official website?

The official website for Glaukos is www.glaukos.com.

Where are Glaukos' headquarters?

Glaukos is headquartered at 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at [email protected], or via fax at 949-367-9984.